Biochemical markers of myocyte injury, such as cTnT, cTnI, H-FABP, and MLC-1, increase in the absence of ischaemic events in heart failure patients with the most adverse long-term outcomes.
Does the measurement of biochemical markers of myocyte injury predict adverse long-term outcomes in patients with chronic congestive heart failure?
Serial measurement of biochemical markers of myocyte injury can help identify chronic heart failure patients at risk for adverse long-term outcomes.
This review discusses the role of biochemical markers of myocyte injury in patients with chronic congestive heart failure. Heart specific assays have been developed for the measurement of cardiac troponin T (cTnT), cardiac troponin I (cTnI), heart type fatty acid binding protein (H-FABP), and myosin light chain 1 (MLC-1). Concentrations of these biochemical markers increase in the absence of ischaemic events in the subset of patients with heart failure whose long term outcomes are most adverse. The markers are easy to measure serially and it is therefore easy to follow patients without inter-observer variability. The serial clinical use of these markers, separately or in combination, will sharpen our understanding of the state of heart failure.
Yukihito Sato (Tue,) conducted a review in chronic congestive heart failure. Biochemical markers of myocyte injury (cTnT, cTnI, H-FABP, MLC-1) was evaluated. Biochemical markers of myocyte injury, such as cTnT, cTnI, H-FABP, and MLC-1, increase in the absence of ischaemic events in heart failure patients with the most adverse long-term outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: